Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

The 194 people with Parkinson’s disease involved in the study from the six research hospitals in the U.K were randomly assigned to inject themselves once a week for 96 weeks with exenatide ...

“It is not yet clear whether there may be a subgroup of people with Parkinson’s disease who may get benefit from the use of exenatide,” he added. He said that there will be more research to ...